Search or ask a question

What is the mean of leukemia?

Myeloid leukemia

Best insight from top research papers

The term "leukemia" refers to a heterogeneous group of hematological malignancies characterized by the abnormal proliferation of lymphoid or hematopoietic cells in the bone marrow and other parts of the body. Leukemia is classified into various types based on factors like cell origin, progression speed, and affected age groups . It is a type of cancer that primarily affects the blood-forming tissues in the body, leading to the overproduction of dysfunctional white blood cells. Leukemia can manifest as acute or chronic forms, with acute leukemia progressing rapidly and chronic leukemia developing more slowly. The incidence of leukemia is increasing globally, necessitating advanced diagnostic technologies for early detection and targeted therapies based on genetic defects. Early diagnosis is crucial due to the challenging nature of detecting leukemia in its initial stages.

Answers from top 5 papers

PDF

Open Access

More filters

Papers (5)	Insight
Monograph•DOI Fast Facts: Leukemia 22 Feb 2022	Not addressed in the paper.
Open access•Posted Content•DOI Leukemia: Cancer of Blood and Bone Marrow M. Bösch 11 Mar 2023	Leukemia is a type of cancer affecting blood and bone marrow, characterized by abnormal white blood cell overproduction. Mean in this context refers to the average, which is not addressed in the paper.
Open access•Book Chapter•DOI Foreword 16 Oct 2022	Leukemia is a hematological malignancy characterized by abnormal cell proliferation in the bone marrow or lymphoid system, with acute and chronic forms classified based on progression speed and cell origin.
Open access•Book Chapter•DOI Preface 16 Oct 2022	Leukemia is a heterogeneous group of hematological malignancies characterized by abnormal cell proliferation in the bone marrow, with over 60,000 new cases diagnosed annually in the United States.
Proceedings Article•DOI Detection of Leukemia using Machine Learning M. Iswarya, A. R, Karpagam. A - Show less +2 more 09 May 2022 4 Citations	Not addressed in the paper.

My columns

Related Questions

What is meaning of cancer?5 answersCancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells undergo uncontrolled proliferation and can invade surrounding tissues and metastasize to other parts of the body. The development of cancer is attributed to genetic mutations that accumulate over time in certain cells. Cancer cells can adopt various tumorigenic processes to metastasize and are subject to evolution by natural selection, leading to genetic and epigenetic changes within the population of cancer cells. The cancer process reprograms fundamental principles of cellular life and harnesses the mechanisms of biological evolution, such as mutation and selection. Cancer can be viewed as a reverse (atavistic) evolution, accompanied by rearrangement of system information and loss of 'social' behavior. Overall, cancer is a complex disease involving the transformation and evolution of cells, leading to uncontrolled proliferation and the ability to invade and spread to other parts of the body.

What is AML?5 answersAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is a clonal malignant disorder of myeloid progenitor cells characterized by uncontrolled proliferation, dysregulation in the differentiation program, and inhibition of apoptosis mechanisms. AML is a rapidly progressing blood cancer involving myeloid stem cells, which fail to differentiate into mature blood cells, resulting in the accumulation of dysfunctional immature cells in the bone marrow and peripheral blood system. It is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding. AML is a group of malignant diseases originating from clonal hematopoietic stem cells, with a prevalence of 2-3 per hundred thousand people all over the world every year.

What is Acute lymphoblastic leukemia?5 answersAcute lymphoblastic leukemia (ALL) is a heterogeneous disease characterized by the clonal replication and accumulation of immature lymphoid cells in the bone marrow and lymph organs. The exact cause of ALL is unknown, but factors such as radiation exposure, chemical exposure, and genetics may play a role. ALL is the most common childhood malignancy, accounting for approximately 25% of childhood cancers. Survival rates for ALL have significantly improved over the years, thanks to collaborative clinical trials and the development of efficient chemotherapeutic regimens. ALL can be diagnosed through blood and bone marrow examinations, and recent advancements in genetic profiling have enhanced our understanding of the disease. Treatment for ALL typically involves poly-chemotherapy, radiation therapy, and hematopoietic stem cell transplantation. However, challenges still remain, including the adverse effects of chemotherapy and poor survival rates in patients with relapsed or refractory ALL. As a result, novel immune-based therapies, such as bi-specific T-cell engagers and chimeric antigen receptor T cells, have been introduced to improve remission rates with reduced toxicity.

What is the definition of cancer?3 answersCancer is a disease characterized by the rapid growth of abnormal cells that can spread beyond their usual boundaries and invade other parts of the body, a process known as metastasis. It is caused by a combination of genetic mutations that accumulate over time in certain cells. Cancer cells undergo uncontrolled proliferation and can adopt various tumorigenic processes to metastasize. These transformed cells are subject to evolution by natural selection, leading to genetic and epigenetic changes that contribute to the lethal phenotype. Cancer can occur in various areas of the body and is classified as either benign or malignant based on its ability to invade and metastasize. Lifestyle choices, viral infections, and certain risk factors can increase the likelihood of developing cancer. Early detection and treatment are crucial for improving outcomes.

What are the subtypes of leukemia according to the World Health Organization?1 answersتصنف منظمة الصحة العالمية (WHO) سرطان الدم النخاعي الحاد (AMLs) إلى أنواع فرعية مختلفة بناءً على الانحرافات الكروموسومية والجينية، مع وجود تنبؤات مختلفة لكل نوع فرعي. يتعرف تصنيف منظمة الصحة العالمية الحالي لـ AML على عدة أنواع فرعية بناءً على السمات السريرية والمورفولوجية والجينية. يستخدم نظام تصنيف منظمة الصحة العالمية للأورام الخبيثة الدموية، بما في ذلك AML، المعلومات الجينية على نطاق واسع للمساعدة في التصنيف. تم تطوير طريقة لتمييز الأنواع الفرعية لـ AML بناءً على مستوى التعبير للعلامات. ابيضاض الدم الحمراء النقي (PEL) هو نوع فرعي نادر من AML تم إعادة تصنيفه إلى فئات أخرى من AML، وخاصة AML مع التغيرات المرتبطة بخلل التنسج النقوي، في نظام تصنيف منظمة الصحة العالمية لعام 2008.

What is the World Health Organization's classification of leukemia?4 answersنشرت منظمة الصحة العالمية (WHO) عدة تصنيفات لسرطان الدم. تم نشر أحدث تصنيف في عام 2022 ويعرف باسم تصنيف منظمة الصحة العالمية 2022. تم تطوير مخطط التصنيف هذا بالتعاون مع تصنيف الإجماع الدولي (ICC) وتوصيات شبكة LeukemiaNet الأوروبية (ELN). أدخل تصنيف منظمة الصحة العالمية 2022 تغييرات على مخططات التصنيف السابقة، بما في ذلك توسيع المجموعة المرتبطة بخلل التنسج النقوي (MDS) وإعادة تصنيف المرضى بناءً على التحليل الوراثي الخلوي. يتم تحديث تصنيف منظمة الصحة العالمية لسرطان الدم بانتظام لدمج المعرفة والتطورات الجديدة في علم الوراثة الجزيئي ويستخدم لتوجيه التشخيص السريري وقرارات العلاج.

See what other people are reading

What is a Metal Organic Framework?

A Metal-Organic Framework (MOF) is a class of multifunctional organometallic compounds composed of metal ions or clusters linked by organic molecules, forming porous structures with large surface areas and high porosity. MOFs have gained attention in various fields due to their exceptional qualities such as biocompatibility, non-toxicity, and tunable porosity, making them ideal for applications in biosensing, drug delivery, and cancer therapies. Despite the wide range of properties and potential applications, MOFs have not been extensively utilized in biomedical practices, but they hold promise for various applications in life sciences, including as carriers for therapeutic molecules, delivery systems, and even as therapeutic agents in photodynamic and sonodynamic therapy. Additionally, MOFs and MOF-derived materials have shown adaptability in environmental biosystems, such as biofuel cells and microbial metal reduction systems.What is the effective plasma concentration of chemo-drug?

The effective plasma concentration of a chemo-drug is crucial for achieving maximum cytotoxic effects while minimizing toxicity. Maintaining plasma drug concentrations within a defined therapeutic range has been shown to improve efficacy and reduce toxicity for various groups of drugs, including antiasthmatic, antiarrhythmic, antibacterial, and antirheumatic drugs. For methotrexate, plasma levels need to be monitored, especially during high-dose therapy, to anticipate toxicity and the potential need for extended citrovorum factor rescue. Additionally, a correlation exists between toxicologic endpoints in animal systems and clinically achievable peak plasma concentrations (PPCs) in humans, aiding in selecting rational starting points for in vitro screening of new agents and in vitro doses for chemosensitivity assays.Can seeking a second opinion improve patient outcomes in healthcare settings?

Seeking a second opinion in healthcare settings can indeed improve patient outcomes. Patients seeking second opinions are often motivated by a desire for more information or reassurance about their diagnosis or treatment. Second opinions can lead to significant changes in diagnosis, staging, and treatment, resulting in reduced costs and improved time to start treatment. Additionally, when done well, external second opinions can help build trust, reduce conflict, and impact clinical management positively. However, discrepancies in opinions between the first and second opinions can have a major impact on patient outcomes in a significant number of cases. Therefore, seeking a second opinion, especially in cases of disagreement or complex medical situations, can contribute to better decision-making, potentially leading to improved patient outcomes in healthcare settings.What is bioinformatic analysis?

Bioinformatic analysis refers to the utilization of computational methods to analyze, interpret, and visualize biological data. It involves extracting valuable information from biological data through the application of computer technology for tasks like storage, analysis, and retrieval of genetic information. Bioinformatics plays a crucial role in various fields such as cancer diagnosis, molecular research, food sciences, and microbiome research. This interdisciplinary field has seen a significant rise in PubMed citations over the years, indicating its growing importance in scientific research. By leveraging bioinformatics tools, researchers can predict bioactivity potential, analyze structures of bioactive peptides, and explore the composition and functions of microbial communities in relation to human health and disease.Why more cancer survivors now?

The increase in the number of cancer survivors can be attributed to advancements in early detection and treatment, along with the aging and growth of the population. As per the collaborative estimates by the American Cancer Society and the National Cancer Institute, the number of cancer survivors in the United States has been steadily rising every three years. These estimates are based on data from cancer registries, vital statistics, and population projections. The prevalence of cancer survivors has been on the rise, with more than 18 million Americans reported to have a history of cancer in 2022. The proactive assessment and management of the unique medical and psychosocial needs of cancer survivors by healthcare providers are crucial in optimizing care for this growing population.What are the long-term health effects of exposure to different levels of radiation?

Exposure to ionizing radiation can lead to various long-term health effects, even at low levels. Studies suggest that radiation exposure is associated with an increased risk of diseases of the circulatory system (DCS), such as heart attacks and strokes, with potential risks observed at doses as low as 0.5 Gy to the heart or brain. Additionally, long-term exposure to ionizing radiation, even below dose limits, has been linked to elevated levels of certain blood biomarkers like interleukin-6 (IL-6) and eosinophils, which can contribute to health issues like cancer. Furthermore, radiation exposure can result in gradual health disorders, increasing the risk of conditions like cancer and cardiovascular disease over time. Understanding the biological effects of radiation is crucial due to the potential long-term consequences, ranging from cancer induction to heart diseases.Is Kdm5d a tumour suppressor in AML?

Kdm5d is not specifically mentioned in the provided contexts. However, the Kdm5 family, including Kdm5b and Kdm5c, has been extensively discussed. Kdm5b has been identified as a tumor suppressor in acute myeloid leukemia (AML) by directly down-regulating AML stemness genes. On the other hand, Kdm5c has been highlighted as a tumor suppressor in AML, showing that reduced Kdm5c expression accelerates AML growth and is associated with a de-differentiation phenotype. These findings emphasize the tumor-suppressive roles of specific Kdm5 family members in AML. Further research may be needed to determine the specific role of Kdm5d in AML.Is Kdm5d a tumour suppressor in leukemia in the context of mosaic loss of chromosome Y?

Yes, KDM5D is implicated as a tumor suppressor in leukemia, particularly in the context of mosaic loss of chromosome Y (mLOY). Studies have shown that loss of KDM5D, a histone 3 lysine 4 demethylase located on the Y chromosome, can lead to increased DNA damage in hematopoietic stem and progenitor cells (HSPCs) and promote leukemogenesis in mice. Additionally, somatic loss of chromosome Y (LOY) has been identified as a recurrent genetic defect in clear cell renal cell carcinoma (ccRCC), leading to downregulation of epigenetic factors like KDM5D, which may contribute to disease progression. These findings highlight the role of KDM5D in suppressing leukemia and suggest its involvement in the pathogenesis of hematopoietic malignancies.Is any molecule that similar structure of derrubone is obtained from natural as HSP 90 inhibitor?

Yes, molecules similar in structure to derrubone have been identified as Hsp90 inhibitors from natural sources. Derrubone, an isoflavone natural product, has been recognized as a potent Hsp90 inhibitor, inducing the degradation of Hsp90 client proteins. Additionally, analogues of derrubone have been synthesized and evaluated for their inhibitory activity against cancer cell lines, showing low micromolar inhibitory effects. Furthermore, the search for novel Hsp90 inhibitors from natural origins has been ongoing, with a focus on diverse pharmacological properties for cancer treatment. This highlights the potential of natural products, like derrubone and its analogues, as promising candidates for Hsp90 inhibition in therapeutic approaches.How does TIM-3's modulation affect the efficacy of cancer immunotherapy in renal cell carcinoma (RCC)?

Modulation of TIM-3 impacts cancer immunotherapy efficacy in renal cell carcinoma (RCC) by regulating immune responses. TIM-3, a negative regulator of immunity, interacts with dendritic cells (DCs) and T cells, influencing T cell activation and trogocytosis. In RCC, TIM-3 blockade disrupts trogocytosis of activated tumor-specific CD8+ T cells, enhancing antitumor immunity and reducing tumor burden. Additionally, TIM-3 and PD-1 blockades synergize to inhibit trogocytosis, promoting T cell survival and tumor control. These findings underscore TIM-3's crucial role in modulating immune responses in RCC and highlight its potential as a target for enhancing cancer immunotherapy efficacy in this context.What is strong evidence between nin-alcoholic fatty liver and PDIA3 IN SCIENTIFIC LITERATURE?

Strong evidence in scientific literature links non-alcoholic fatty liver disease (NAFLD) to PDIA3. Clement et al. demonstrated that a high-fat and high-fructose diet induced liver damage by promoting major histocompatibility complex class II (MHC-II) presentation of PDIA3 peptides, leading to pathogenic T and B cell responses. Additionally, Huang and Chuang highlighted the association between genetic variants like PNPLA3 and the outcomes of autoimmune hepatitis (AIH), emphasizing the impact of PNPLA3-rs738409 GG variant on clinical endpoints of AIH. Furthermore, Rausch and Mueller discussed the role of PNPLA3 in liver damage, showing that PNPLA3 GG correlated with signs of liver damage in heavy drinkers, suggesting a connection between PNPLA3 and liver pathology. These findings collectively underscore the significant relationship between NAFLD and PDIA3, shedding light on the mechanisms underlying liver damage in metabolic disorders.